menu

mTOR Inhibitors Market

Schedule Call

mTOR Inhibitors Market

mTOR Inhibitors Market by Devices (Imaging Devices, Monitoring Devices), End User (Diagnostic Centers, Hospital) – Global Outlook & Forecast 2023-2031

GR - 660979 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: April 19, 2023

Historical Years – 2021  |  Base Year – 2022  |  Forecasted Years – 2023-2031


mTOR Inhibitors Market Scope

Report Attribute

Details

Market Size Value in 2022

US$ 6.70 Billion

Market Size Value in 2031

US$ 9.84 billion

CAGR

4.36%

Base Year For Estimation

2022

Forecast Period

2023 to 2031

Historical Year

2021

Segments Covered

Drug Type, Indication, Route of Administration, Distribution Channel, and Region

Regional Scope

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global mTOR inhibitors market was valued at US$ 6.70 billion in 2022 and is expected to register a revenue CAGR of 4.36% to reach US$ 9.84 billion by 2031.

mTOR Inhibitors Market Fundamentals                                                              

mTOR (mammalian target of rapamycin) inhibitors are a class of drugs that target the mTOR protein, a central regulator of cell growth and metabolism. The mTOR pathway plays a key role in regulating cell growth, proliferation, and survival, and its dysregulation is associated with many diseases, including cancer, diabetes, and neurodegenerative disorders. These inhibitors work by blocking the activity of the mTOR protein, which reduces the production of proteins and other cellular components necessary for cell growth and division. By doing so, they can slow down or stop the growth of cancer cells. There are two main classes of mTOR inhibitors: Rapalogs and ATP-competitive. Rapalogs are derived from the natural product rapamycin and work by binding to a specific protein called FKBP12, which in turn binds to mTOR and inhibits its activity. ATP-competitive inhibitors bind to the ATP-binding site of mTOR and inhibit its activity differently. mTOR inhibitors have been approved to treat certain types of cancer, including renal cell carcinoma, breast cancer, and pancreatic neuroendocrine tumors. They are also being studied in non-cancerous diseases such as autoimmune disorders and neurodegenerative diseases. 

[145]

mTOR Inhibitors Market Dynamics

The mTOR inhibitors market is expected to show lucrative revenue growth during the forecast period. With the growing incidence of cancer worldwide, the demand for mTOR inhibitors is expected to rise. Technological advances have led to the development of new mTOR inhibitors with improved efficacy and fewer side effects, driving market revenue growth. As the global population ages, age-related diseases are also increasing. This is expected to drive the demand for mTOR inhibitors, commonly used in treating these diseases. Pharmaceutical companies are investing heavily in research and development activities to develop new and innovative mTOR inhibitors, expected to drive market revenue growth during the forecast period. There is a growing awareness among patients and healthcare professionals about the importance of early diagnosis and effective treatment of cancer. This is expected to increase the demand for mTOR inhibitors, considered an important tool in the fight against cancer. Governments worldwide are promoting research and development, which is expected to further drive the need for the mTOR inhibitors market during the forecast period.

The mTOR inhibitors market is subject to stringent regulations by various regulatory bodies, which can hinder the market’s revenue growth. The cost of mTOR inhibitors is high, making it difficult for patients to afford treatment. Besides, mTOR inhibitors can cause various side effects, including stomatitis, diarrhea, and infections, which can limit their use in patients. The efficacy of mTOR inhibitors is limited in some cancers, which can limit their use in these indications. Several alternative therapies are available for cancer treatment, which restricts the revenue growth of the mTOR inhibitors market. Some cancer cells can develop resistance to mTOR inhibitors, which can limit their effectiveness. There is limited awareness about mTOR inhibitors among patients and physicians, which can limit their adoption.

mTOR Inhibitors Market Ecosystem

The global mTOR inhibitors have been analyzed from five perspectives: drug type, indication, route of administration, distribution channel, and region. 

mTOR Inhibitors Market by Drug Type

[1023]

Based on drug type, the global mTOR inhibitors market is segmented into Everolimus, Temsirolimus, Sirolimus, and others.

The everolimus segment accounts for a prominent revenue share in the global mTOR inhibitors market. Everolimus works by interfering with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal body cells can also be affected, other unwanted effects will also occur. It belongs to the medicines known as antineoplastics (cancer medicines). Drugs like Everolimus and Letrozole have succeeded in slowing tumor development by either eradicating the cells or preventing them from growing or spreading. Everolimus is a drug that belongs to the class of mTOR (mammalian target of rapamycin) inhibitors, which treat various types of cancer, including renal cell carcinoma, breast cancer, and pancreatic neuroendocrine tumors. The dominance of Everolimus in the global mTOR inhibitor market can be attributed to several factors. Everolimus has been approved for treating multiple types of cancers, making it a versatile drug that can treat many patients. This has allowed Everolimus to capture a larger market share than other mTOR inhibitors approved for a more limited range of indications. Moreover, Everolimus has a favorable safety profile compared to other mTOR inhibitors. The drug is generally well-tolerated by patients and has fewer adverse events than other drugs. 

mTOR Inhibitors Market by Indication

Based on indication, the global mTOR inhibitors market is segmented into oncology, immunosuppressant, organ transplantation, and others. 

The oncology segment dominates the global mTOR inhibitor market with the largest revenue share. The mTOR pathway plays a key role in cancer cell growth and survival, making it an attractive target for cancer therapy. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, with an estimated 10 million deaths in 2020. As the global burden of cancer continues to increase, there is a growing demand for effective cancer therapies, including mTOR inhibitors. In addition, a favorable regulatory environment supports the oncology segment of the mTOR inhibitor market. Regulatory agencies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have granted fast-track and priority review status to several mTOR inhibitors in oncology, allowing for expedited approval and faster patient access to these drugs.

mTOR Inhibitors Market by Route of Administration

Based on the route of administration, the global mTOR inhibitors market is segmented into oral and intravenous.

Oral mTOR inhibitors are more convenient for patients as they can be self-administered at home without needing hospital visits. This makes them more appealing to patients who want to maintain their quality of life while receiving treatment. Oral mTOR inhibitors are highly effective in the treatment of various diseases. They work by inhibiting the activity of the mammalian target of rapamycin (mTOR) protein, which plays a critical role in the growth and proliferation of cancer cells. Oral mTOR inhibitors are generally safe and well-tolerated by patients. They have a favorable side-effect profile compared to other cancer treatments, such as chemotherapy. Oral mTOR inhibitors are often less expensive than other cancer treatments, which makes them more accessible to patients who may not have insurance or who have limited financial resources. Oral mTOR inhibitors are widely available and can be prescribed by doctors in most countries. This makes them a popular choice for physicians who want to provide their patients with effective treatment options.

mTOR Inhibitors Market by Distribution Channel

Based on the distribution channel, the global mTOR inhibitors market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies.

The hospital segment accounts for the largest global mTOR inhibitor market revenue share. The use of mTOR inhibitors for cancer treatment requires close monitoring and management due to the complex nature of the treatment. This complexity often requires hospitalization and the involvement of specialized medical personnel. Therefore, the hospital segment dominates as they have the resources and personnel to manage the complexities associated with mTOR inhibitor therapy. Hospitals have access to specialized equipment and facilities required to administer and monitor mTOR inhibitors. This equipment includes infusion pumps, specialized laboratory equipment, and monitoring devices for safe and effective treatment. Mammalian targets of rapamycin (mTOR) inhibitors are classified as high-risk drugs, and their use requires strict adherence to regulatory requirements. Hospitals can meet these requirements due to their established infrastructure, policies, and procedures. Physicians specializing in cancer treatment may prefer to administer mTOR inhibitors in a hospital setting due to the complexities associated with the treatment. The hospital setting provides a controlled environment where patients can be closely monitored, and any adverse reactions can be promptly managed.

mTOR Inhibitors Market by Region

Based on the region, the global mTOR inhibitors market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America’s highly advanced healthcare infrastructure includes well-established hospitals, specialized cancer treatment centers, and research institutions. This infrastructure supports the development and distribution of mTOR inhibitors, contributing to the region’s dominance in the global market. North America has a high prevalence of cancer, which has driven the demand for mTOR inhibitors. The region has an increased incidence of various types of cancer, including breast, lung, and prostate, contributing to the market revenue growth. North America has a high level of healthcare spending, which has supported the development and distribution of mTOR inhibitors. The region’s high healthcare spending has enabled the development of advanced medical technologies, including mTOR inhibitors, which have contributed to the region’s dominance in the global mTOR inhibitors market revenue share. North America’s strong pharmaceutical industry has been at the forefront of mTOR inhibitor research and development. 

mTOR Inhibitors Market Competitive Landscape

The prominent players operating in the global mTOR inhibitors market are:

mTOR Inhibitors Market Strategic Development

  • In February 2022, Cambrian Biopharma, a multi-asset longevity biotech, signed a deal with Novartis to pursue innovative, selective medicines created and defined by Novartis to target the mTOR pathway. The licensed assets were structural analogs of the FDA-approved medication rapamycin, which has been demonstrated in mice to prevent or repair several age-related health impairments and to increase average lifespan by up to 31%.

Frequently Asked Questions About This Report

The global mTOR inhibitors market is expected to grow at a revenue CAGR of 4.36% during the forecast period.

Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., and Zydus Lifesciences Limited are the key players operating in the global mTOR inhibitors market.

The oncology segment accounts for the largest global mTOR inhibitors market revenue share.

Europe accounts for the second-largest revenue share in the global mTOR inhibitors market.

Stringent regulatory policies, the high cost of mTOR inhibitors, and the side effects of mTOR inhibitors are among the major challenges in global mTOR inhibitors market revenue expansion.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem 
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions       
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022)
    3. Regulatory Landscape
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints
    3. Opportunities
  5. GLOBAL mTOR INHIBITORS MARKET- ANALYSIS & FORECAST, BY DRUG TYPE
    1. Everolimus
    2. Temsirolimus
    3. Sirolimus
    4. Others
  6. GLOBAL mTOR INHIBITORS MARKET- ANALYSIS & FORECAST, BY INDICATION
    1. Immunosuppressant
    2. Oncology
    3. Organ Transplantation
    4. Others
  7. GLOBAL mTOR INHIBITORS MARKET- ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
    1. Oral
    2. Intravenous 
  8. GLOBAL mTOR INHIBITORS MARKET- ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies
  9. GLOBAL mTOR INHIBITORS MARKET- ANALYSIS & FORECAST, BY REGION
    1. North America mTOR Inhibitors Market
      1. North America mTOR Inhibitors Market, by Drug Type
      2. North America mTOR Inhibitors Market, by Indication
      3. North America mTOR Inhibitors Market, by Route of Administration
      4. North America mTOR Inhibitors Market, by Distribution Channel
      5. North America mTOR Inhibitors Market, by Country
        1. U.S.
          1. U.S. mTOR Inhibitors Market, by Drug Type
          2. U.S. mTOR Inhibitors Market, by Indication
          3. U.S. mTOR Inhibitors Market, by Route of Administration
          4. U.S. mTOR Inhibitors Market, by Distribution Channel
        2. Canada
          1. Canada mTOR Inhibitors Market, by Drug Type
          2. Canada mTOR Inhibitors Market, by Indication
          3. Canada mTOR Inhibitors Market, by Route of Administration
          4. Canada mTOR Inhibitors Market, by Distribution Channel
    2. Europe mTOR Inhibitors Market
      1. Europe mTOR Inhibitors Market, by Drug Type
      2. Europe mTOR Inhibitors Market, by Indication
      3. Europe mTOR Inhibitors Market, by Route of Administration
      4. Europe mTOR Inhibitors Market, by Distribution Channel
      5. Europe mTOR Inhibitors Market, by Country/Region
        1.  Germany
          1. Germany mTOR Inhibitors Market, by Drug Type
          2. Germany mTOR Inhibitors Market, by Indication
          3. Germany mTOR Inhibitors Market, by Route of Administration
          4. Germany mTOR Inhibitors Market, by Distribution Channel
        2. U.K.
          1. U.K. mTOR Inhibitors Market, by Drug Type
          2. U.K. mTOR Inhibitors Market, by Indication
          3. U.K. mTOR Inhibitors Market, by Route of Administration
          4. U.K. mTOR Inhibitors Market, by Distribution Channel
        3. France
          1. France mTOR Inhibitors Market, by Drug Type
          2. France mTOR Inhibitors Market, by Indication
          3. France mTOR Inhibitors Market, by Route of Administration
          4. France mTOR Inhibitors Market, by Distribution Channel
        4. Spain
          1. Spain mTOR Inhibitors Market, by Drug Type
          2. Spain mTOR Inhibitors Market, by Indication
          3. Spain mTOR Inhibitors Market, by Route of Administration
          4. Spain mTOR Inhibitors Market, by Distribution Channel
        5. Italy
          1. Italy mTOR Inhibitors Market, by Drug Type
          2. Italy mTOR Inhibitors Market, by Indication
          3. Italy mTOR Inhibitors Market, by Route of Administration
          4. Italy mTOR Inhibitors Market, by Distribution Channel
        6. Rest of Europe
          1. Rest of Europe mTOR Inhibitors Market, by Drug Type
          2. Rest of Europe mTOR Inhibitors Market, by Indication
          3. Rest of Europe mTOR Inhibitors Market, by Route of Administration
          4. Rest of Europe mTOR Inhibitors Market, by Distribution Channel
    3. Asia Pacific mTOR Inhibitors Market
      1. Asia Pacific mTOR Inhibitors Market, by Drug Type
      2. Asia Pacific mTOR Inhibitors Market, by Indication
      3. Asia Pacific mTOR Inhibitors Market, by Route of Administration
      4. Asia Pacific mTOR Inhibitors Market, by Distribution Channel
      5. Asia Pacific mTOR Inhibitors Market, by Country/Region
        1. China
          1. China mTOR Inhibitors Market, by Drug Type
          2. China mTOR Inhibitors Market, by Indication
          3. China mTOR Inhibitors Market, by Route of Administration
          4. China mTOR Inhibitors Market, by Distribution Channel
        2. Japan
          1. Japan mTOR Inhibitors Market, by Drug Type
          2. Japan mTOR Inhibitors Market, by Indication
          3. Japan mTOR Inhibitors Market, by Route of Administration
          4. Japan mTOR Inhibitors Market, by Distribution Channel
        3. India
          1. India mTOR Inhibitors Market, by Drug Type
          2. India mTOR Inhibitors Market, by Indication
          3. India mTOR Inhibitors Market, by Route of Administration
          4. India mTOR Inhibitors Market, by Distribution Channel
        4. South Korea
          1. South Korea mTOR Inhibitors Market, by Drug Type
          2. South Korea mTOR Inhibitors Market, by Indication
          3. South Korea mTOR Inhibitors Market, by Route of Administration
          4. South Korea mTOR Inhibitors Market, by Distribution Channel
        5. Australia
          1. Australia mTOR Inhibitors Market, by Drug Type
          2. Australia mTOR Inhibitors Market, by Indication
          3. Australia mTOR Inhibitors Market, by Route of Administration
          4. Australia mTOR Inhibitors Market, by Distribution Channel
        6. Rest of Asia Pacific 
          1. Rest of Asia Pacific mTOR Inhibitors Market, by Drug Type
          2. Rest of Asia Pacific mTOR Inhibitors Market, by Indication
          3. Rest of Asia Pacific mTOR Inhibitors Market, by Route of Administration
          4. Rest of Asia Pacific mTOR Inhibitors Market, by Distribution Channel
    4. Latin America mTOR Inhibitors Market
      1. Latin America mTOR Inhibitors Market, by Drug Type
      2. Latin America mTOR Inhibitors Market, by Indication 
      3. Latin America mTOR Inhibitors Market, by Route of Administration
      4. Latin America mTOR Inhibitors Market, by Distribution Channel 
      5. Latin America mTOR Inhibitors Market, by Country/ Region
        1. Brazil
          1. Brazil mTOR Inhibitors Market, by Drug Type
          2. Brazil mTOR Inhibitors Market, by Indication 
          3. Brazil mTOR Inhibitors Market, by Route of Administration
          4. Brazil mTOR Inhibitors Market, by Distribution Channel 
        2. Mexico
          1. Mexico mTOR Inhibitors Market, by Drug Type
          2. Mexico mTOR Inhibitors Market, by Indication 
          3. Mexico mTOR Inhibitors Market, by Route of Administration 
          4. Mexico mTOR Inhibitors Market, by Distribution Channel
        3. Argentina
          1. Argentina mTOR Inhibitors Market, by Drug Type
          2. Argentina mTOR Inhibitors Market, by Indication 
          3. Argentina mTOR Inhibitors Market, by Route of Administration
          4. Argentina mTOR Inhibitors Market, by Distribution Channel 
        4. Rest of Latin America
          1. Rest of Latin America mTOR Inhibitors Market, by Drug Type 
          2. Rest of Latin America mTOR Inhibitors Market, by Indication
          3. Rest of Latin America mTOR Inhibitors Market, by Route of Administration 
          4. Rest of Latin America mTOR Inhibitors Market, by Distribution Channel
    5. Middle East & Africa mTOR Inhibitors Market
      1. Middle East & Africa mTOR Inhibitors Market, by Drug Type
      2. Middle East & Africa mTOR Inhibitors Market, by Indication 
      3. Middle East & Africa mTOR Inhibitors Market, by Route of Administration
      4. Middle East & Africa mTOR Inhibitors Market, by Distribution Channel 
      5. Middle East & Africa a mTOR Inhibitors Market, by Country/ Region
        1. GCC Countries
          1. GCC Countries mTOR Inhibitors Market, by Drug Type
          2. GCC Countries mTOR Inhibitors Market, by Indication 
          3. GCC Countries mTOR Inhibitors Market, by Route of Administration
          4. GCC Countries mTOR Inhibitors Market, by Distribution Channel 
        2. South Africa
          1. South Africa mTOR Inhibitors Market, by Drug Type
          2. South Africa mTOR Inhibitors Market, by Indication 
          3. South Africa mTOR Inhibitors Market, by Route of Administration 
          4. South Africa mTOR Inhibitors Market, by Distribution Channel
        3. Rest of Middle East & Africa
          1. Rest of Middle East & Africa mTOR Inhibitors Market, by Drug Type
          2. Rest of Middle East & Africa mTOR Inhibitors Market, by Indication 
          3. Rest of Middle East & Africa mTOR Inhibitors Market, by Route of Administration
          4. Rest of Middle East & Africa mTOR Inhibitors Market, by Distribution Channel 
  10. COMPANY PROFILES         
    1. Novartis AG
      1. Business Snapshot 
      2. Products Offered
      3. Financial Details
      4. Strategic Development
    2. Pfizer Inc.
    3. Teva Pharmaceutical Industries Ltd.
    4. Zydus Lifesciences Limited
    5. Dr. Reddy’s Laboratories Ltd.
    6. Hikma Pharmaceuticals Plc.
    7. Glenmark Pharmaceuticals Ltd.
    8. Alkem Laboratories Ltd.
    9. Accord Healthcare Inc.
    10. Gland Pharma Ltd.

*Insights on financial performance are subject to the availability of information in the public domain

List of Tables

 

  1. Global mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  2. Global mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  3. Global mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  4. Global mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million)
  5. Global mTOR Inhibitors Market, by Region, 2021-2031 (US$ Million)  
  6. North America mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  7. North America mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  8. North America mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  9. North America mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million) 
  10. North America mTOR Inhibitors Market, by Country, 2021-2031 (US$ Million) 
  11. U.S. mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  12. U.S. mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  13. U.S. mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  14. U.S. mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million) 
  15. Canada mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  16. Canada mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  17. Canada mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  18. Canada mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million) 
  19. Europe mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  20. Europe mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  21. Europe mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  22. Europe mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million) 
  23. Europe mTOR Inhibitors Market, by Country/ Region, 2021-2031 (US$ Million) 
  24. Germany mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  25. Germany mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  26. Germany mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  27. Germany mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million) 
  28. U.K. mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  29. U.K. mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  30. U.K. mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  31. U.K. mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million) 
  32. France mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  33. France mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  34. France mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  35. France mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million) 
  36. Italy mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  37. Italy mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  38. Italy mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  39. Italy mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million) 
  40. Spain mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  41. Spain mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  42. Spain mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  43. Spain mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million) 
  44. Rest of Europe mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  45. Rest of Europe mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  46. Rest of Europe mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  47. Rest of Europe mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million) 
  48. Asia Pacific mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  49. Asia Pacific mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  50. Asia Pacific mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  51. Asia Pacific mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million) 
  52. Asia Pacific mTOR Inhibitors Market, by Country/ Region, 2021-2031 (US$ Million) 
  53. China mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  54. China mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  55. China mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  56. China mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million)
  57. Japan mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  58. Japan mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  59. Japan mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  60. Japan mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million) 
  61. India mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  62. India mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  63. India mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  64. India mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million) 
  65. South Korea mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  66. South Korea mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  67. South Korea mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million) 
  68. Australia mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  69. Australia mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  70. Australia mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  71. Australia mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million) 
  72. Rest of Asia Pacific mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  73. Rest of Asia Pacific mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  74. Rest of Asia Pacific mTOR Inhibitors Market, by Route of Administration, 2021-2031 (US$ Million)
  75. Rest of Asia Pacific mTOR Inhibitors Market, by Distribution Channel, 2021-2031 (US$ Million)
  76. Latin America mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million) 
  77. Rest of Asia Pacific mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  78. Latin America mTOR Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  79. Latin America mTOR Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  80. Latin America mTOR Inhibitors Market, by Country/ Region, 2021–2031 (US$ Million)
  81. Brazil mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  82. Brazil mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  83. Brazil mTOR Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  84. Brazil mTOR Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  85. Mexico mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  86. Mexico mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  87. Mexico mTOR Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  88. Mexico mTOR Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  89. Argentina mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  90. Argentina mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  91. Argentina mTOR Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  92. Argentina mTOR Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  93. Rest of Latin America mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  94. Rest of Latin America mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  95. Rest of Latin America mTOR Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  96. Rest of Latin America mTOR Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million)
  97. Middle East and Africa mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  98. Middle East and Africa mTOR Inhibitors Market1, by Indication, 2021-2031 (US$ Million) 
  99. Middle East and Africa mTOR Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  100. Middle East and Africa mTOR Inhibitors Market, by Distribution Channel 2021–2031 (US$ Million)
  101. Middle East and Africa mTOR Inhibitors Market, by Country/ Region, 2021–2031 (US$ Million)
  102. GCC Countries mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  103. GCC Countries mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  104. GCC Countries mTOR Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  105. GCC Countries mTOR Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  106. South Africa mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million)
  107. South Africa mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  108. South Africa mTOR Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  109. South Africa mTOR Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million) 
  110. Rest of Middle East & Africa mTOR Inhibitors Market, by Drug Type, 2021-2031 (US$ Million) 
  111. Rest of Middle East & Africa mTOR Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  112. Rest of Middle East & Africa mTOR Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  113. Rest of Middle East & Africa mTOR Inhibitors Market, by Distribution Channel, 2021–2031 (US$ Million)

List of Figures

 

  1. mTOR Inhibitors Market Ecosystem  
  2. Snapshot of Global mTOR Inhibitors Market, 2021 & 2031
  3. Snapshot of Global mTOR Inhibitors Market, by Region, 2021 & 2031 
  4. Global mTOR Inhibitors Market: COVID-19 Pandemic Impact Assessment 
  5. Global mTOR Inhibitors Market: Key Players & Competitive Positioning (2022) 
  6. mTOR Inhibitors: Market Dynamics 
  7. Global mTOR Inhibitors Market for Everolimus, 2021-2031 (US$ Million) 
  8. Global mTOR Inhibitors Market for Temsirolimus, 2021-2031 (US$ Million) 
  9. Global mTOR Inhibitors Market for Sirolimus, 2021-2031 (US$ Million)
  10. Global mTOR Inhibitors Market for Others, 2021-2031 (US$ Million)
  11. Global mTOR Inhibitors Market for Oncology, 2021-2031 (US$ Million) 
  12. Global mTOR Inhibitors Market for Immunosuppressant, 2021-2031 (US$ Million)
  13. Global mTOR Inhibitors Market for Organ Transplantation, 2021-2031 (US$ Million)
  14. Global mTOR Inhibitors Market for Others, 2021-2031 (US$ Million) 
  15. Global mTOR Inhibitors Market for Oral, 2021-2031 (US$ Million)
  16. Global mTOR Inhibitors Market for Intravenous, 2021-2031 (US$ Million)
  17. Global mTOR Inhibitors Market for Hospital Pharmacies, 2021-2031 (US$ Million)
  18. Global mTOR Inhibitors Market for Retail Pharmacies, 2021-2031 (US$ Million)
  19. Global mTOR Inhibitors Market for Online Pharmacies, 2021-2031 (US$ Million)
  20. North America mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  21. U.S. mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  22. Canada mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  23. Europe mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  24. Germany mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  25. U.K. mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  26. France mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  27. Italy mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  28. Spain mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  29. Rest of Europe mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  30. Asia Pacific mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  31. China mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  32. Japan mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  33. India mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  34. South Korea mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  35. Australia mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  36. Rest of Asia Pacific mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  37. Latin America mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  38. Brazil mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  39. Mexico mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  40. Argentina mTOR Inhibitors Market, 2021-2031 (US$ Million)
  41. Rest of Latin America mTOR Inhibitors Market, 2021-2031 (US$ Million)
  42. Middle East & Africa mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  43. GCC Countries mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  44. South Africa mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  45. Rest of Middle East & Africa mTOR Inhibitors Market, 2021-2031 (US$ Million) 
  46. Novartis AG Revenue from 2019 Onwards (US$ Million)
  47. Pfizer Inc. Revenue from 2019 Onwards (US$ Million)
  48. Teva Pharmaceutical Industries Ltd. Revenue from 2019 Onwards (US$ Million)
  49. Zydus Lifesciences Limited Revenue from 2019 Onwards (US$ Million)
  50. Dr. Reddy’s Laboratories Ltd. Revenue from 2019 Onwards (US$ Million)
  51. Hikma Pharmaceuticals Plc. Revenue from 2019 Onwards (US$ Million)
  52. Glenmark Pharmaceuticals Ltd. Revenue from 2019 Onwards (US$ Million)
  53. Alkem Laboratories Ltd. Revenue from 2019 Onwards (US$ Million)
  54. Accord Healthcare Inc. Revenue from 2019 Onwards (US$ Million)
  55. Gland Pharma Ltd. Revenue from 2019 Onwards (US$ Million)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the mTOR Inhibitors Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the mTOR Inhibitors Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?